Literature DB >> 19352394

Imaging techniques for prostate cancer: implications for focal therapy.

Baris Turkbey1, Peter A Pinto, Peter L Choyke.   

Abstract

The multifocal nature of prostate cancer has necessitated whole-gland therapy in the past; however, since the widespread use of PSA screening, patients frequently present with less-advanced disease. Many men with localized disease wish to avoid the adverse effects of whole-gland therapy; therefore, focal therapy for prostate cancer is being considered as a treatment option. For focal treatment to be viable, accurate imaging is required for diagnosis, staging, and monitoring of treatment. Developments in MRI and PET have brought more attention to prostate imaging and the possibility of improving the accuracy of focal therapy. In this Review, we discuss the advantages and disadvantages of conventional methods for imaging the prostate, new developments for targeted imaging, and the possible role of image-guided biopsy and therapy for localized prostate cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19352394      PMCID: PMC3520096          DOI: 10.1038/nrurol.2009.27

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  96 in total

1.  Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization.

Authors:  Jeong Kon Kim; Seong Sook Hong; Young Jun Choi; Seong Ho Park; Hanjong Ahn; Choung-Soo Kim; Kyoung-Sik Cho
Journal:  J Magn Reson Imaging       Date:  2005-11       Impact factor: 4.813

2.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.

Authors:  David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

3.  Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging.

Authors:  Stefano Cirillo; Massimo Petracchini; Lorenza Scotti; Teresa Gallo; Annalisa Macera; Maria Cristina Bona; Cinzia Ortega; Pietro Gabriele; Daniele Regge
Journal:  Eur Radiol       Date:  2008-09-30       Impact factor: 5.315

4.  Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy.

Authors:  P E Levesque; P T Nieh; L N Zinman; D W Seldin; J A Libertino
Journal:  Urology       Date:  1998-06       Impact factor: 2.649

5.  Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging.

Authors:  K K Yu; J Scheidler; H Hricak; D B Vigneron; C J Zaloudek; R G Males; S J Nelson; P R Carroll; J Kurhanewicz
Journal:  Radiology       Date:  1999-11       Impact factor: 11.105

6.  Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy.

Authors:  Tim Joseph; David A McKenna; Antonio C Westphalen; Fergus V Coakley; Shoujun Zhao; Ying Lu; I-Chow Hsu; Mack Roach; John Kurhanewicz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-28       Impact factor: 7.038

7.  Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy.

Authors:  Anurag K Singh; Jochen Kruecker; Sheng Xu; Neil Glossop; Peter Guion; Karen Ullman; Peter L Choyke; Bradford J Wood
Journal:  BJU Int       Date:  2007-12-05       Impact factor: 5.588

8.  Peripheral zone hypoechoic lesions of the prostate: evaluation with contrast-enhanced gray scale transrectal ultrasonography.

Authors:  Jie Tang; Jing Chun Yang; Yanmi Li; Junlai Li; Huaiyin Shi
Journal:  J Ultrasound Med       Date:  2007-12       Impact factor: 2.153

9.  Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis.

Authors:  Tsutomu Tamada; Teruki Sone; Yoshimasa Jo; Akira Yamamoto; Takenori Yamashita; Naoto Egashira; Shigeki Imai; Masao Fukunaga
Journal:  Radiology       Date:  2008-06-06       Impact factor: 11.105

10.  Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy.

Authors:  Alexandre Ben Cheikh; Nicolas Girouin; Marc Colombel; Jean-Marie Maréchal; Albert Gelet; Alvine Bissery; Muriel Rabilloud; Denis Lyonnet; Olivier Rouvière
Journal:  Eur Radiol       Date:  2008-10-17       Impact factor: 5.315

View more
  48 in total

1.  A high-affinity, high-stability photoacoustic agent for imaging gastrin-releasing peptide receptor in prostate cancer.

Authors:  Jelena Levi; Ataya Sathirachinda; Sanjiv S Gambhir
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

2.  Prostate cancer diagnosis: the feasibility of needle-based optical coherence tomography.

Authors:  Berrend G Muller; Daniel M de Bruin; Willemien van den Bos; Martin J Brandt; Juliette F Velu; Mieke T J Bus; Dirk J Faber; Dilara Savci; Patricia J Zondervan; Theo M de Reijke; Pilar Laguna Pes; Jean de la Rosette; Ton G van Leeuwen
Journal:  J Med Imaging (Bellingham)       Date:  2015-07-09

3.  Comparing nonrigid registration techniques for motion corrected MR prostate diffusion imaging.

Authors:  C Buerger; J Sénégas; S Kabus; H Carolus; H Schulz; H Agarwal; B Turkbey; P L Choyke; S Renisch
Journal:  Med Phys       Date:  2015-01       Impact factor: 4.071

4.  Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  Clin Transl Imaging       Date:  2017-04-10

5.  Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer.

Authors:  Eric D Pressly; Richard A Pierce; Luke A Connal; Craig J Hawker; Yongjian Liu
Journal:  Bioconjug Chem       Date:  2013-01-11       Impact factor: 4.774

6.  Amide proton transfer MR imaging of prostate cancer: a preliminary study.

Authors:  Guang Jia; Ronney Abaza; JoAnna D Williams; Debra L Zynger; Jinyuan Zhou; Zarine K Shah; Mitva Patel; Steffen Sammet; Lai Wei; Robert R Bahnson; Michael V Knopp
Journal:  J Magn Reson Imaging       Date:  2011-03       Impact factor: 4.813

7.  Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT : Clinical results and quality of life.

Authors:  Marsha Schlenter; Vanessa Berneking; Barabara Krenkel; Felix M Mottaghy; Thomas-Alexander Vögeli; Michael J Eble; Michael Pinkawa
Journal:  Strahlenther Onkol       Date:  2018-03-06       Impact factor: 3.621

8.  Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer.

Authors:  Hari Trivedi; Baris Turkbey; Ardeshir R Rastinehad; Compton J Benjamin; Marcelino Bernardo; Thomas Pohida; Vijay Shah; Maria J Merino; Bradford J Wood; W Marston Linehan; Aradhana M Venkatesan; Peter L Choyke; Peter A Pinto
Journal:  Urology       Date:  2012-01       Impact factor: 2.649

Review 9.  MRI of localized prostate cancer: coming of age in the PSA era.

Authors:  Barış Türkbey; Marcelino Bernardo; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  Diagn Interv Radiol       Date:  2011-09-16       Impact factor: 2.630

10.  Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate.

Authors:  Takahito Nakajima; Makoto Mitsunaga; Neil H Bander; Warren D Heston; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2011-07-27       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.